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Warren Bickel: The paper provides a good general
overview of the changes that have taken place in
methadone treatment over the years. Its basic mes-
sage is appropriate: Methadone treatment is effective
and is being more widely accepted.
George Bigelow: Yes. I do think, though, that the
paper overstates the extent to which methadone treat-
ment has entered the medical mainstream. Mr. Marion’s
program is in New York City, where methadone has
a longer history and more public support than many
or most other places.
Bickel:  I agree. The State of Vermont, for example,
has one methadone clinic, which has a waiting list of
over a hundred people. Here in Arkansas, we only
have two methadone programs in the Little Rock area.
This article serves as a reminder that methadone is
effective, and therefore we need to do what we can to
continue to bolster its acceptance by both the public
and the medical and rehabilitation communities.
Kyle Kampman: Many programs still have difficulty
recruiting for medical staff positions. And while there
may be less stigma today, plenty still exists—not only
against methadone and methadone patients, but also
extending to physicians and psychiatrists who work
with them.
Bigelow: Overall, nationwide, I don’t think there is
any other medication that is so effective and yet so
hard to get as methadone.
Older patients, younger patients
Bigelow: Mr. Marion describes the aging of the
methadone population, which of course is testimony
to the effectiveness of the treatment. Methadone has
significantly extended the life expectancy of opiate
abusers. One corollary has been the creation of a group
of patients with more concurrent medical disorders
of the type that all aging populations have, such as
hypertension and diabetes. Our group recently pub-
lished a study on this issue and the challenges it will
create for treatment providers [Lofwall et al., 2005].
Kampman: Partly because of the medical problems
related to aging, and partly due to opioid abusers’
high propensity for trauma, we see a lot of patients
with pain. Many come to us through referrals from
pain management specialists who are apprehensive
about treating opiate-dependent patients. Chronic
pain is a difficult problem to manage anywhere,
and perhaps more so in a methadone clinic. We would
greatly benefit from new research in this area.
Bickel: The larger number of new, young opioid-
dependent patients speaks to the need to have mul-
tiple treatment options. It is not helpful to place a
person who has recently become involved with pre-
scription drugs in treatment with patients having
extensive histories of drug dependence. We need to
expand the range of options, so that different types
of patients can receive appropriate treatments.
Bigelow: One respect in which our experience seems
to differ from Mr. Marion’s is the 60 percent figure
he cites for treatable depression among methadone
patients. That is considerably higher than we see in
Baltimore. I can’t think of a reason why there should
be such a difference, except perhaps that Mr. Marion’s
figure reflects assessments made at intake. We find
that many of our patients are depressed because of
the difficulties of the opioid-abusing lifestyle, but
their mood recovers once they are normalized on
methadone.
Treatment models and settings
Bickel: I think it is very important to keep in mind
that methadone is only one part of the larger treat-
ment picture. The research agenda should include
how we can best utilize both methadone and buprenor-
phine to provide a true continuum of care where every
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patient receives treatment in an appropriate modal-
ity. The interesting questions in methadone research
right now aren’t about its efficacy as a pharmacolog-
ical agent—that was established long ago. They are
about the different ways of delivering methadone and
how to best incorporate social and behavioral coun-
seling in the treatment.
Bigelow: For example, Mr. Marion talks about
methadone medical maintenance, where stabilized
patients can transfer their visits from the clinic to a
physician’s office. I think we should keep striving to
develop models like that, so that patients and physi-
cians can have maximum flexibility in the choice of
treatments as well as treatment settings.
Bickel: Tom McLellan’s group [McLellan et al., 1993]
examined the importance of counseling, medical care,
and psychosocial services with respect to the outcomes
of methadone patients. They concluded you could
make methadone treatment outcomes look either hor-
rible or successful based on the quantity and quality
of accompanying psychosocial treatments.
Bigelow: I agree. The psychosocial and behavioral
treatments that accompany the pharmacotherapies
are critically important, if only because they can be
applied to the full range of substance abuse disorders.
The drawback of a medication such as methadone is
that it is pharmacologically specific—it will only treat
opioid addiction—whereas today’s patients tend to
be polydrug abusers. 
Bickel: Our group has been looking at different ways
of delivering psychotherapies. Recently we completed
a trial where we compared the results of computer-
delivered cognitive-behavioral treatment with the
same treatment delivered by a therapist, along with a
control treatment. So far, the results appear to show
that the computer- and therapist-delivered treatments
were better than the control, but not significantly dif-
ferent from each other, suggesting that we may be able
to use computer technology to expand access to
psychotherapies.
Bigelow: The NIDA Clinical Trials Network has con-
ducted a study of the effectiveness of motivational
incentives to reduce stimulant abuse in methadone
clinics. Though the data are still in review, the incen-
tives appear to have had a positive impact, as meas-
ured by the frequency of stimulant-negative urine
samples during treatment. Another area where I think
significant research is needed is the development of
longer acting methadone dosage forms, which would
make the medication more convenient while also
reducing the risk of overdose and diversion.
Unfortunately, I don’t think anyone is looking into
this. &
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